In one study, concomitant mutations in the KEAP1‐NRF2 pathway in EGFR‐mutant NSCLC were associated with a shorter PFS among patients who were mostly treated with first‐ and second‐generation EGFR‐TKIs (4.7 vs. 13.0 months, p = 0.0014), but most of those mutations occurred in KEAP1 or NFE2L2 [3]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.